Journal article · 2026 · Open access
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
CA A Cancer Journal for Clinicians, 76(2), e70071 · Published 1 March 2026 · DOI 10.3322/caac.70071
In brief
“Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study” is a 2026 journal article by J. Duan and 25 co-authors, published in CA A Cancer Journal for Clinicians. OpenAlex counts 15 citations as of 18 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at CA A Cancer Journal for Clinicians.
- Citations
- 15
- Most cited in
- 2026 (15)
- Field-weighted impact
- 47.13
- References
- 24
- Authors
- 26
Abstract
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for advanced, EGFR-mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co-existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third-generation EGFR-TKI aumolertinib in combination with carboplatin-pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with EGFR mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy (n = 62) or monotherapy (n = 64). The primary end point was median progression-free survival (PFS). At a median follow-up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co-existing tumor protein p53 (TP53) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug-related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin-pemetrexed for this molecularly defined population.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Duan, J., Zhong, J., Sun, B., Zhao, W., Wu, L., Fei, K., Chu, Q., Guo, Q., Song, Q., Yu, Y., Zhu, D., Liu, X., Zhao, J., Zhan, Z., Li, S., Nie, L., Lin, J., Peng, X., Zhong, D., . . . Wang, J. (2026). Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study. CA A Cancer Journal for Clinicians, 76(2), e70071. https://doi.org/10.3322/caac.70071
MLA 9
Duan, J., et al. “Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study.” CA A Cancer Journal for Clinicians, vol. 76, no. 2, 2026, p. e70071. https://doi.org/10.3322/caac.70071.
Chicago
Duan, J., Jia Zhong, Boyang Sun, Wen‐Hua Zhao, Lin Wu, Kailun Fei, Qian Chu, et al. 2026. “Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study.” CA A Cancer Journal for Clinicians 76 (2): e70071. https://doi.org/10.3322/caac.70071.
Harvard
Duan, J. et al. (2026) ‘Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study’, CA A Cancer Journal for Clinicians, 76(2), p. e70071. doi:10.3322/caac.70071.
IEEE
J. Duan et al., “Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study,” CA A Cancer Journal for Clinicians, vol. 76, no. 2, p. e70071, 2026, doi: 10.3322/caac.70071.
BibTeX
@article{duan2026aumolertinib,
title = {{Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study}},
author = {Duan, J. and Zhong, Jia and Sun, Boyang and Zhao, Wen‐Hua and Wu, Lin and Fei, Kailun and Chu, Qian and Guo, Qi‐Sen and Song, Qibin and Yu, Yan and Zhu, Da‐Xing and Liu, Xinyan and Zhao, Jun and Zhan, Zhi‐Xiang and Li, Shi and Nie, Lei and Lin, J. and Peng, Xiao‐Dong and Zhong, Diansheng and Zhou, Jin and Li, Li‐Hua and Chen, Yunfang and Hu, Chen and Mok, Tony S.K. and Wang, Zhijie and Wang, Jie},
journal = {CA A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {2},
pages = {e70071},
doi = {10.3322/caac.70071},
url = {https://doi.org/10.3322/caac.70071}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- aumolertinib
- non-small cell lung cancer
- EGFR mutation
- tumor suppressor mutations
- TP53 mutation
- EGFR tyrosine kinase inhibitors
- combination chemotherapy
- progression-free survival
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Duan, J., Zhong, J., Sun, B., Zhao, W., Wu, L., Fei, K., Chu, Q., Guo, Q., Song, Q., Yu, Y., Zhu, D., Liu, X., Zhao, J., Zhan, Z., Li, S., Nie, L., Lin, J., Peng, X., Zhong, D., . . . Wang, J. (2026). Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study. CA A Cancer Journal for Clinicians, 76(2), e70071. https://doi.org/10.3322/caac.70071
How many times has this paper been cited?
15 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at CA A Cancer Journal for Clinicians: sign in and open the full text from this page.
Who wrote this paper?
J. Duan, Jia Zhong, Boyang Sun, Wen‐Hua Zhao, Lin Wu, Kailun Fei, Qian Chu, Qi‐Sen Guo, Qibin Song, Yan Yu, Da‐Xing Zhu, Xinyan Liu and 14 more.
What is the DOI of this paper?
10.3322/caac.70071, permanently at https://doi.org/10.3322/caac.70071. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.